Cllia Coutzac

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/731504/clelia-coutzac-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. <i>Nature Communications</i> , 2020 , 11, 2168	17.4	95
8	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019 , 106, 106-114	7.5	30
7	Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?. <i>Bulletin Du Cancer</i> , 2019 , 106, 105-113	2.4	22
6	Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting. <i>BMC Medical Research Methodology</i> , 2018 , 18, 67	4.7	O
5	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018 , 67, 2056-2067	19.2	109
4	Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. <i>Seminars in Immunopathology</i> , 2017 , 39, 327-331	12	16
3	Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. <i>Journal of Crohn</i> and Colitis, 2017, 11, 1238-1246	1.5	79
2	IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists. <i>Journal of Immunology</i> , 2016 , 197, 168-78	5.3	31
1	Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. <i>Hepatology</i> , 2014 , 60, 65-76	11.2	100